Large-scale Study Finds No Evidence of Liver Toxicity from Oral CBD Products

Photo: Pexels

This article originally appeared in Presence Marketing’s April 2021 Industry Newsletter

By Steven Hoffman

CBD products do not cause liver damage when taken orally, according to preliminary results of a seven-month clinical investigation conducted by Validcare in response to the FDA’s request to help inform the agency’s regulatory approach regarding products containing hemp-derived CBD. Twelve companies, including CBD market leader Charlotte’s Web, helped support the study. Preliminary findings showed no evidence of liver disease in the 839 participants in the study, and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions. The Validcare study’s findings were shared with the FDA when researchers met with the agency on March 15 to review preliminary liver safety results in the form of an abstract, reported Nutra Ingredients-USA. “We are encouraged by these findings and hopeful this study provides FDA with sufficient science-based data to determine and take action on a safe regulatory path forward,” said Keith Aqua, M.D., co-principal investigator of the study.